Oncolytic Virus Therapies Market Size Report 2023-2028

Elena Anderson, Marketing Manager |

Author:

Report DescriptionAbout IMARC Group

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Global Oncolytic Virus Therapies Market Research Report:

According to the latest report by IMARC Group, titled “ Oncolytic Virus Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Fore cast 2023-2028

” the global oncolytic virus therapies market reached a strong growth in 2022.

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

Request Free Sample Report:

https://www.imarcgroup.com/oncolytic-virus-therapies-market/requestsample

Report Description Report Description and Highlights

Global Oncolytic Virus Therapies Market Trends :

The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).

Report Description Report Description and Highlights

Market Summary:

Breakup by Virus Type:

• Genetically Engineered Oncolytic Viruses

• Herpes Simplex Virus

• Adenovirus

• Vaccinia Virus

• Oncolytic Wild-Type Viruses

• Reovirus

• Newcastle Disease Virus

• Vesicular Stomatitis Virus

Breakup by Application:

• Solid Tumors

• Breast Cancer

• Prostate Cancer

• Lung Cancer

• Glioblastoma

• Melanoma

• Hematological Malignancies

• Lymphoma

• Leukemia

• Myeloma

Breakup by End Use:

• Hospitals

• Specialty Clinics

• Cancer Research Institute

Breakup by Region:

• North America

• United States

• Canada

• Asia-Pacific

• China

• Japan

• India

• South Korea

• Australia

• Indonesia

Report Description Report Description and Highlights

• Others

• Europe

• Germany

• France

• United Kingdom

• Italy

• Spain

• Russia

• Others

• Latin America

• Brazil

• Mexico

• Others

• Middle East and Africa

Note: We are updating our reports, If you want latest primary and secondary data (2023-2028) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report.

Report Description Report Description and Highlights

Competitive Landscape with Key Players:

Dnatrix Inc.

Genelux Corporation

Lokon Pharma AB

Replimune Group Inc.

Rigvir Ltd.

Sorrento Therapeutics

Takara Bio Inc. (Takara Holdings Inc.)

Targovax

TILT Biotherapeutics Ltd

Transgene SA and Vyriad. Kindly note that this only represents a partial list of companies

• and the complete list has been provided in the report.

View Full Report with TOC & List of Figure:

https://www.imarcgroup.com/oncolytic-virus-therapies-market

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

Report Description Report Description and Highlights

© 2019 IMARC All Rights Reserved

This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.